Mail

AXGN - AxoGen, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

19.41

-0.72 (-3.58%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	20.13
Open	20.07
Bid	19.45 x 800
Ask	19.45 x 1200
Day's Range	19.41 - 20.60
52 Week Range	14.13 - 56.85
Volume	146,841
Avg. Volume	414,180

Market Cap	760.973M
Beta (3Y Monthly)	0.59
PE Ratio (TTM)	N/A
EPS (TTM)	-0.69
Earnings Date	Oct 31, 2017 - Nov 6, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	2010-01-27
1y Target Est	33.50

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire2 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of AxoGen, Inc. - AXGN
NEW YORK, July 19, 2019 -- Levi & Korsinsky announces it has commenced an investigation of AxoGen, Inc. (NASDAQCM: AXGN) concerning possible breaches of fiduciary duty. To.
Simply Wall St.last month
Have Insiders Been Selling AxoGen, Inc. (NASDAQ:AXGN) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Insider Monkeylast month
Here’s What Hedge Funds Think About AxoGen, Inc. (AXGN)
Is AxoGen, Inc. (NASDAQ:AXGN) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
GlobeNewswire2 months ago
Axogen, Inc. to Participate at Upcoming Investor Conferences
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that members of its management team will participate in three upcoming investor conferences during June. Karen Zaderej, chairman, CEO, and president will present at the Jefferies 2019 Healthcare Conference in New York City. Peter J. Mariani, chief financial officer, will present at the William Blair 39th Annual Growth Stock Conference in Chicago.
Motley Fool2 months ago
AxoGen Inc (AXGN) Q1 2019 Earnings Call Transcript
AXGN earnings call for the period ending March 31, 2019.
Zacks2 months ago
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Associated Press2 months ago
AxoGen: 1Q Earnings Snapshot
On a per-share basis, the Alachua, Florida-based company said it had a loss of 24 cents. Losses, adjusted for stock option expense and non-recurring costs, were 15 cents per share. The results did not ...
GlobeNewswire2 months ago
Axogen, Inc. Reports 2019 First Quarter Financial Results
ALACHUA, Fla., May 08, 2019 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
GlobeNewswire3 months ago
Axogen, Inc. Appoints New Members to Board of Directors
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced it increased the size of its Board of Directors to nine members and appointed Quentin S. Blackford and Alan M. Levine to fill the open positions effective May 15, 2019. Blackford was also appointed to the Audit Committee, and Levine was appointed to the Audit Committee and the Governance and Nominating Committee.
Zacks3 months ago
Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswire3 months ago
Axogen, Inc. Announces Completion of Planned Interim Analysis and One-Time Enrollment Expansion for RECON® Study
The study will support the submission of a Biologic License Application (BLA) to the FDA for Avance® Nerve Graft. The FDA-approved RECON Study design includes a Statistical Analysis Plan that outlines a blinded interim analysis of the pooled standard deviation for the primary endpoint measure from the first 80 enrolled subjects. The pooled standard deviation is a key statistical assumption used to determine the appropriate sample size for the study.
GlobeNewswire3 months ago
Axogen, Inc. to Report First Quarter 2019 Financial Results and Host Conference Call on May 8, 2019
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2019 financial results on Wednesday, May 8, 2019 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
Simply Wall St.3 months ago
Is There An Opportunity With AxoGen, Inc.'s (NASDAQ:AXGN) 48% Undervaluation?
How far off is AxoGen, Inc. (NASDAQ:AXGN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to toda...
PR Newswire4 months ago
Lifshitz & Miller LLP Announces Investigation of 22nd Century Group, Activision Blizzard, Inc., Astec Industries, Inc., Avon Products, Inc., Axogen, Inc., Everquote Inc. and Health Insurance Innovations, Inc.
NEW YORK , March 22, 2019 /PRNewswire/ -- 22 nd Century Group (XXII) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that XXII's stock ...
Business Wire4 months ago
Robbins Arroyo LLP: AxoGen, Inc. (AXGN) Misled Shareholders According to Class Action
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of AxoGen, Inc. (AXGN) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1933 and Securities Act of 1934 pursuant to the company's November 2017 Secondary Public Offering ("SPO") and/or May 2018 SPO and/or between August 7, 2017 and December 18, 2018. AxoGen develops and markets surgical solutions for peripheral nerves.
GlobeNewswire4 months ago
CLASS ACTION UPDATE for AXGN, MKL, VALE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, March 11, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
ACCESSWIRE4 months ago
FINAL DEADLINE - (AXGN) AxoGen, Inc. - Bronstein, Gewirtz & Grossman, LLC
NEW YORK, NY / ACCESSWIRE / March 11, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AxoGen, Inc. ("AxoGen" or the "Company") ...
Business Wire4 months ago
AXOGEN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against AxoGen, Inc. - AXGN
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (AXGN). Investor losses must relate to purchases of the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018. This action is pending in the United States District Court for the Middle District of Florida.
GlobeNewswire4 months ago
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AxoGen, Markel, Maxar, and Wirecard and Encourages Investors to Contact the Firm
NEW YORK, March 10, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of AxoGen, Inc., Markel.
ACCESSWIRE4 months ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AXGN, MAXR and ATVI
NEW YORK, NY / ACCESSWIRE / March 10, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
Business Wire4 months ago
AXOGEN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against AxoGen, Inc. - AXGN
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (AXGN). Investor losses must relate to purchases of the Company’s securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018.
GlobeNewswire4 months ago
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AxoGen, Inc. (“AxoGen” or “the Company”) (NASDAQ: AXGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s shares pursuant to and/or traceable to AxoGen’s Registration Statement and Prospectus issued in connection to the Company’s November 2017 secondary public offering (“November SPO”), and/or the Company’s Registration Statement and Prospectus issued in connection with the Company’s May 2018 secondary public offering (“May SPO”), and/or between August 7, 2017, and December 18, 2018, inclusive (“the Class Period”), are encouraged to contact the firm before March 11, 2019.
GlobeNewswire4 months ago
KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for AXOGEN, INC. Investors – AXGN
FINAL DEADLINE REMINDER: AxoGen investors may, no later than March 11, 2019, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, AxoGen provides surgical solutions for physical damage or discontinuity to peripheral nerves.